Remove tag stakeholders
article thumbnail

Smart pharmaceutical and healthcare labels: Lets trace medicines from its origin

Roots Analysis

It is worth noting that smart labels contain a transponder code which can be read by sophisticated devices, including radio frequency identification device (RFID) tags and near-field communication (NFC) chips. While most smartphones can read NFC chips, RFID tags can only be read by specialized receivers.

article thumbnail

Grand Rounds September 29, 2023: Navigating the Use of Patient-Reported Outcomes in Research and Practice: The PROTEUS Consortium (Claire Snyder, PhD; Norah Crossnohere, PhD; Anne Schuster, PhD)

Rethinking Clinical Trials

The PROTEUS Consortium partners with key stakeholder groups to disseminate and implement tools that have been developed to optimize the use of PROs in clinical trials and practice. With current funding, PROTEUS can address recommendations specifically regarding education materials. We are pursuing funding.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Grand Rounds October 28, 2022: The HERO (Healthcare Worker Exposure Response & Outcomes) Program: An Online Community to Support Observational Studies, Randomized Trials, and Long-Term Safety Surveillance (Emily O’Brien, PhD, FAHA; Russell Rothman, MD, MPP)

Rethinking Clinical Trials

– The creative multi-faceted approach to recruitment that includes diverse stakeholder engagement could be successful in creating research registries for other important health issues. pctGR, @Collaboratory1.

Trials 130
article thumbnail

Anti-Counterfeiting Technologies in Healthcare

Roots Analysis

Examples of such technologies include DNA Taggants (a unique DNA tag used in the product / packaging that can be scanned using a designated instrument / equipment), invisible printing technologies, digital watermark technologies and hidden markers / print technologies.

article thumbnail

Grand Rounds Ethics and Regulatory Series October 14, 2022: Responding (or Not) to Signals of Potential Clinical Significance in Pragmatic Clinical Trials (Joseph Ali, JD; Tanya Matthews, PhD; Leslie J. Crofford, MD)

Rethinking Clinical Trials

What do patients and other stakeholders desire? This raises a lot of questions: Whose responsibility is it to monitor those risk factors? What should be monitored and how? Who can and should act/respond? There is a possible for risk-signaling data to “slip between the cracks.”. In the second example, they were not able to.

article thumbnail

Grand Rounds July 15, 2022: Overview of Accelerating COVID-19 Therapeutic Interventions and Vaccines (ACTIV) Public-Private Partnership and Lessons Learned (Stacey J. Adam, PhD)

Rethinking Clinical Trials

. – Foundation for NIH was involved from the beginning because we had successfully done the public-private partnerships for other initiatives, we had the stakeholder relationships to get everyone to the table, and our involvement allowed for rapid, targeted donations from private sector. pctGR, @Collaboratory1.

article thumbnail

Amylyx ALS drug draws criticism over $158,000 price tag

pharmaphorum

Most patients are only now being enrolled in Europe, according to co-chief executive officers of Amylyx Justin Klee and Joshua Cohen, who say they arrived at the price following discussions with patients, as well as insurers and other stakeholders, but also mindful of future funding of research. ALS affects over 30,000 people in the US.

Drugs 52